Citrullinated histone H3, a biomarker for neutrophil extracellular trap formation, predicts the risk of mortality in patients with cancer.
arterial thromboembolism
cancer-associated thrombosis
citrullinated histone H3
mortality
neutrophil extracellular traps
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
03
12
2018
accepted:
19
02
2019
pubmed:
11
4
2019
medline:
27
5
2020
entrez:
11
4
2019
Statut:
ppublish
Résumé
Prior studies indicate that neutrophil extracellular traps (NETs) are associated with arterial thromboembolism (ATE) and mortality. We investigated the association between NET formation biomarkers (citrullinated histone H3 [H3Cit], cell-free DNA [cfDNA], and nucleosomes) and the risk of ATE and all-cause mortality in patients with cancer. In this prospective cohort study, H3Cit, cfDNA and nucleosome levels were determined at study inclusion, and patients with newly diagnosed cancer or progressive disease after remission were followed for 2 years for ATE and death. Nine-hundred and fifty-seven patients were included. The subdistribution hazard ratios for ATE of H3Cit, cfDNA and nucleosomes were 1·0 per 100 ng/ml increase (95% confidence interval [95% CI]: 0·7-1·4, P = 0·949), 1·0 per 100 ng/ml (0·9-1·2, P = 0·494) increase and 1·1 per 1-unit increase (1·0-1·2, P = 0·233), respectively. Three-hundred and seventy-eight (39·5%) patients died. The hazard ratio (HR) for mortality of H3Cit and cfDNA per 100 ng/ml increase was 1·1 (1·0-1·1, P < 0·001) and 1·1 (1·0-1·1, P < 0·001), respectively. The HR for mortality of nucleosome levels per 1-unit increase was 1·0 (1·0-1·1, P = 0·233). H3Cit, cfDNA and nucleosome levels were not associated with the risk of ATE in patients with cancer. Elevated H3Cit and cfDNA levels were associated with higher mortality in patients with cancer.
Identifiants
pubmed: 30968400
doi: 10.1111/bjh.15906
pmc: PMC6618331
doi:
Substances chimiques
Biomarkers, Tumor
0
Histones
0
Neoplasm Proteins
0
Types de publication
Clinical Trial
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
311-320Subventions
Organisme : Austrian Science Fund FWF
ID : F 5405
Pays : Austria
Informations de copyright
© 2019 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
Cancer. 1994 Apr 15;73(8):2013-26
pubmed: 8156506
Free Radic Biol Med. 2016 Jul;96:462-4
pubmed: 27040582
PLoS One. 2018 Jan 11;13(1):e0191231
pubmed: 29324871
IUBMB Life. 2019 Feb;71(2):277-282
pubmed: 30414358
Cardiovasc Drugs Ther. 2011 Oct;25(5):419-29
pubmed: 21947818
J Am Coll Cardiol. 2017 Aug 22;70(8):926-938
pubmed: 28818202
J Thromb Haemost. 2015 Mar;13(3):390-7
pubmed: 25529107
Science. 1986 Apr 4;232(4746):34-47
pubmed: 3513311
Haematologica. 2018 Sep;103(9):1549-1556
pubmed: 29794142
Blood. 2010 Dec 9;116(24):5377-82
pubmed: 20829374
Diabetes Care. 2007 Nov;30(11):2945-50
pubmed: 17686833
Blood. 2014 May 1;123(18):2768-76
pubmed: 24366358
Proc Natl Acad Sci U S A. 1987 Aug;84(16):5928-31
pubmed: 3475709
Cell Mol Life Sci. 2014 Nov;71(21):4179-94
pubmed: 25070012
Thromb Res. 2016 Mar;139:56-64
pubmed: 26916297
Atherosclerosis. 1989 Nov;80(1):57-62
pubmed: 2604757
Obes Res Clin Pract. 2018 Mar - Apr;12(2):195-203
pubmed: 28619601
Proc Natl Acad Sci U S A. 2013 May 21;110(21):8674-9
pubmed: 23650392
Nat Rev Cancer. 2011 Jun;11(6):426-37
pubmed: 21562580
Thromb Haemost. 2011 Apr;105(4):586-96
pubmed: 21225099
Nat Rev Immunol. 2013 Jan;13(1):34-45
pubmed: 23222502
Thromb Res. 2018 Apr;164 Suppl 1:S48-S53
pubmed: 29306575
Immunol Res. 2017 Jun;65(3):706-712
pubmed: 28161762
Blood. 2015 Mar 19;125(12):1948-56
pubmed: 25624317
Thromb Haemost. 2018 Jun;118(6):1078-1087
pubmed: 29672788
Control Clin Trials. 1996 Aug;17(4):343-6
pubmed: 8889347
Crit Rev Oncol Hematol. 2014 Nov;92(2):71-82
pubmed: 24878433
J Thromb Haemost. 2012 Jan;10(1):136-44
pubmed: 22044575
J Exp Med. 2012 Apr 9;209(4):819-35
pubmed: 22451716
Blood. 2008 Oct 1;112(7):2703-8
pubmed: 18539899
Ann Neurol. 2017 Aug;82(2):223-232
pubmed: 28696508
Front Immunol. 2013 Jan 09;3:413
pubmed: 23316198
Science. 2004 Mar 5;303(5663):1532-5
pubmed: 15001782
Int J Inflam. 2017;2017:4915062
pubmed: 28828191
Acta Neuropathol. 2015 Feb;129(2):239-57
pubmed: 25548073
Int J Clin Exp Pathol. 2015 Nov 01;8(11):14075-86
pubmed: 26823721
Circ Res. 2015 Mar 27;116(7):1182-92
pubmed: 25547404
J Biol Chem. 1997 Aug 22;272(34):20963-6
pubmed: 9261091
Arterioscler Thromb Vasc Biol. 2018 Apr;38(4):892-902
pubmed: 29437577
J Natl Cancer Inst. 2012 Dec 5;104(23):1837-40
pubmed: 23093559
J Am Stat Assoc. 2019;114(525):259-270
pubmed: 31073256
Eur Heart J. 2016 May 14;37(19):1538-49
pubmed: 26761950
Proc Natl Acad Sci U S A. 2012 Aug 7;109(32):13076-81
pubmed: 22826226
J Natl Cancer Inst. 2007 Aug 15;99(16):1232-9
pubmed: 17686822
Curr Oncol Rep. 2012 Aug;14(4):295-306
pubmed: 22532265
Arthritis Rheumatol. 2017 Mar;69(3):655-667
pubmed: 27696751
Thromb Haemost. 2017 Oct 5;117(10):1919-1929
pubmed: 28837206
Sci Rep. 2018 Aug 23;8(1):12641
pubmed: 30140006
J Clin Invest. 2013 Jul 1;:
pubmed: 23863628
Radiother Oncol. 2011 Aug;100(2):167-75
pubmed: 21752480
Arterioscler Thromb Vasc Biol. 2012 Aug;32(8):1777-83
pubmed: 22652600
J Thromb Haemost. 2018 Mar;16(3):508-518
pubmed: 29325226
PLoS One. 2016 May 02;11(5):e0154484
pubmed: 27136460
Biochemistry (Mosc). 2014 Dec;79(12):1286-96
pubmed: 25716722
Arterioscler Thromb Vasc Biol. 2013 Aug;33(8):2032-2040
pubmed: 23818485
Thromb Haemost. 2013 Feb;109(2):290-7
pubmed: 23238559
J Clin Oncol. 2009 Sep 1;27(25):4124-9
pubmed: 19636003
Proc Natl Acad Sci U S A. 2010 Sep 7;107(36):15880-5
pubmed: 20798043